Insider Selling: NeoGenomics (NASDAQ:NEO) Director Sells $59,916.03 in Stock

NeoGenomics, Inc. (NASDAQ:NEO) Director Lynn Tetrault sold 5,307 shares of NeoGenomics stock in a transaction that occurred on Tuesday, June 9th. The stock was sold at an average price of $11.29, for a total transaction of $59,916.03. Following the transaction, the director owned 91,422 shares in the company, valued at approximately $1,032,154.38. The trade was a 5.49% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

NeoGenomics Trading Down 2.8%

NASDAQ NEO opened at $11.15 on Friday. NeoGenomics, Inc. has a twelve month low of $4.72 and a twelve month high of $13.74. The company has a debt-to-equity ratio of 0.41, a quick ratio of 4.06 and a current ratio of 4.42. The stock has a market cap of $1.45 billion, a price-to-earnings ratio of -14.48 and a beta of 1.82. The firm’s 50 day moving average price is $9.08 and its two-hundred day moving average price is $10.32.

NeoGenomics (NASDAQ:NEO) last posted its quarterly earnings data on Tuesday, April 28th. The medical research company reported $0.01 earnings per share for the quarter, hitting the consensus estimate of $0.01. NeoGenomics had a negative net margin of 13.30% and a negative return on equity of 2.80%. The firm had revenue of $186.67 million for the quarter, compared to analysts’ expectations of $184.54 million. NeoGenomics’s revenue was up 11.3% on a year-over-year basis. Equities analysts anticipate that NeoGenomics, Inc. will post -0.15 EPS for the current year.

Hedge Funds Weigh In On NeoGenomics

Several institutional investors and hedge funds have recently modified their holdings of the stock. First Horizon Corp grew its holdings in shares of NeoGenomics by 52.6% during the 4th quarter. First Horizon Corp now owns 2,509 shares of the medical research company’s stock valued at $30,000 after acquiring an additional 865 shares in the last quarter. Aster Capital Management DIFC Ltd grew its holdings in shares of NeoGenomics by 42.5% during the 3rd quarter. Aster Capital Management DIFC Ltd now owns 3,341 shares of the medical research company’s stock valued at $26,000 after acquiring an additional 997 shares in the last quarter. State of Alaska Department of Revenue grew its holdings in shares of NeoGenomics by 1.7% during the 4th quarter. State of Alaska Department of Revenue now owns 73,044 shares of the medical research company’s stock valued at $858,000 after acquiring an additional 1,215 shares in the last quarter. Choreo LLC grew its holdings in shares of NeoGenomics by 2.2% during the 4th quarter. Choreo LLC now owns 61,462 shares of the medical research company’s stock valued at $752,000 after acquiring an additional 1,313 shares in the last quarter. Finally, GAMMA Investing LLC grew its holdings in shares of NeoGenomics by 68.2% during the 4th quarter. GAMMA Investing LLC now owns 3,602 shares of the medical research company’s stock valued at $42,000 after acquiring an additional 1,460 shares in the last quarter. 98.50% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several research firms have weighed in on NEO. UBS Group reiterated a “hold” rating on shares of NeoGenomics in a research report on Wednesday, February 18th. Benchmark upgraded shares of NeoGenomics from a “hold” rating to a “buy” rating and set a $11.00 price objective on the stock in a research report on Wednesday, April 29th. Leerink Partners upgraded shares of NeoGenomics from a “market perform” rating to an “outperform” rating and lifted their price objective for the stock from $12.00 to $25.00 in a research report on Wednesday, April 29th. Piper Sandler boosted their price target on shares of NeoGenomics from $12.00 to $13.00 and gave the company an “overweight” rating in a report on Tuesday, February 24th. Finally, William Blair restated a “market perform” rating on shares of NeoGenomics in a report on Monday, March 16th. Six research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $13.86.

About NeoGenomics

NeoGenomics, traded on the Nasdaq under the symbol NEO, is a leading provider of cancer-focused genetic and molecular testing services. Headquartered in Fort Myers, Florida, the company operates an integrated network of CAP-accredited and CLIA-certified laboratories across the United States, Europe and Asia. NeoGenomics delivers diagnostic insights that support oncologists, pathologists and healthcare institutions in the detection, prognosis and treatment of hematologic and solid tumor cancers.

The company’s core service offerings include flow cytometry, immunohistochemistry, fluorescence in situ hybridization (FISH), karyotyping and advanced molecular assays such as next-generation sequencing (NGS) panels and polymerase chain reaction (PCR) tests.